New insights into the genetics of primary open-angle glaucoma based on meta-analyses of intraocular pressure and optic disc characteristics. by Springelkamp, H. (Henriët) et al.
A S S O C I A T I O N S T U D I E S A R T I C L E
New insights into the genetics of primary open-angle
glaucoma based on meta-analyses of intraocular
pressure and optic disc characteristics
Henri€et Springelkamp1,2,†, Adriana I. Iglesias1–3,†, Aniket Mishra4,5,†, Rene´
Ho¨hn6,7†, Robert Wojciechowski8–10†, Anthony P. Khawaja11, Abhishek Nag12,
Ya Xing Wang13,14, Jie Jin Wang15, Gabriel Cuellar-Partida4, Jane Gibson16,
Jessica N. Cooke Bailey17, Eranga N. Vithana18–20, Puya Gharahkhani4,
Thibaud Boutin21, Wishal D. Ramdas2, Tanja Zeller22,23, Robert N. Luben24,
Ekaterina Yonova-Doing12, Ananth C. Viswanathan11, Seyhan Yazar25,
Angela J. Cree26, Jonathan L. Haines17, Jia Yu Koh18, Emmanuelle Souzeau27,
James F. Wilson21,28, Najaf Amin1, Christian Mu¨ller22,23, Cristina Venturini12,
Lisa S. Kearns29, Jae Hee Kang30, NEIGHBORHOOD Consortium‡, Yih Chung
Tham18,20, Tiger Zhou27, Elisabeth M. van Leeuwen1, Stefan Nickels7, Paul
Sanfilippo25,29, Jiemin Liao18,20, Herma van der Linde3, Wanting Zhao18,19,
Leonieke M.E. van Koolwijk1, Li Zheng18,31, Fernando Rivadeneira1,32,33,
Mani Baskaran18–20, Sven J. van der Lee1, Shamira Perera18,19, Paulus T.V.M.
de Jong34–36, Ben A. Oostra3, Andre´ G. Uitterlinden1,32,33, Qiao Fan18, Albert
Hofman1,33, E-Shyong Tai19,37,38, Johannes R. Vingerling2, Xueling Sim38,
Roger C.W. Wolfs2, Yik Ying Teo38,39, Hans G. Lemij40, Chiea Chuen Khor18,31,41,
Rob Willemsen3, Karl J Lackner42, Tin Aung18,20, Nomdo M. Jansonius43, Grant
Montgomery44, Philipp S Wild45–47, Terri L. Young48, Kathryn P. Burdon49,
Pirro G. Hysi12, Louis R. Pasquale30,50, Tien Yin Wong18–20, Caroline C.W.
Klaver1,2, Alex W. Hewitt29,49, Jost B. Jonas51, Paul Mitchell15, Andrew J
Lotery26, Paul J. Foster11, Veronique Vitart21, Norbert Pfeiffer7, Jamie E.
Craig27, David A. Mackey25,49,¶, Christopher J. Hammond12,¶, Janey L.
†These authors contributed equally to this work.
‡Membership of the NEIGHBORHOOD Consortium is listed in the Supplementary Material.
¶These authors jointly supervised this work.
Received: May 14, 2016. Revised: August 19, 2016. Accepted: September 28, 2016
VC The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com
1
Human Molecular Genetics, 2017, Vol. 0, No. 0 1–16
doi: 10.1093/hmg/ddw399
Advance Access Publication Date: 6 February 2017
Association Studies Article
Wiggs50,¶, Ching-Yu Cheng18–20,¶, Cornelia M. van Duijn1,¶ and Stuart
MacGregor4,*,¶
1Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands, 2Department of
Ophthalmology, Erasmus Medical Center, Rotterdam, the Netherlands, 3Department of Clinical Genetics,
Erasmus Medical Center, Rotterdam, the Netherlands, 4Statistical Genetics, QIMR Berghofer Medical Research
Institute, Royal Brisbane Hospital, Brisbane, Australia, 5Department of Complex Trait Genetics, VU University,
Center for Neurogenomics and Cognitive Research, Amsterdam, the Netherlands, 6Department of
Ophthalmology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland, 7Department of
Ophthalmology, University Medical Center Mainz, Mainz, Germany, 8Computational and Statistical Genomics
Branch, National Human Genome Research Institute (NIH), Baltimore, MD, USA, 9Department of Epidemiology,
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 10Wilmer Eye Institute, Johns Hopkins
School of Medicine, Baltimore, MD, USA, 11NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS
Foundation Trust and UCL Institute of Ophthalmology, London, UK, 12Department of Twin Research and
Genetic Epidemiology, King’s College London, London, UK, 13Beijing Institute of Ophthalmology, Beijing
Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China, 14Beijing
Ophthalmology and Visual Science Key Lab, Beijing, China, 15Centre for Vision Research, Department of
Ophthalmology and Westmead Institute for Medical Research, University of Sydney, Sydney, New South
Wales, Australia, 16Centre for Biological Sciences, Faculty of Natural and Environmental Sciences, University of
Southampton, Southampton, UK, 17Department of Epidemiology and Biostatistics, Case Western Reserve
University, Cleveland, Ohio, USA, 18Singapore Eye Research Institute, Singapore National Eye Centre,
Singapore, Singapore, 19Duke-National University of Singapore Graduate Medical School, Singapore, Singapore,
20Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
21Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of
Edinburgh, Edinburgh, UK, 22Clinic for General and Interventional Cardiology, University Heart Center
Hamburg, Hamburg, Germany, 23German Center for Cardiovascular Research (DZHK), Partner Site Hamburg,
Luebeck, Kiel, Hamburg/Germany, 24Department of Public Health and Primary Care, Institute of Public Health,
University of Cambridge School of Clinical Medicine, Cambridge, UK, 25Centre for Ophthalmology and Visual
Science, Lions Eye Institute, University of Western Australia, Perth, Australia, 26Clinical and Experimental
Sciences, Faculty of Medicine, University of Southampton, Southampton, UK, 27Department of Ophthalmology,
Flinders University, Adelaide, Australia, 28Centre for Global Health Research, The Usher Institute for
Population Health Sciences and Informatics, University of Edinburgh, Scotland, UK, 29Centre for Eye Research
Australia (CERA), University of Melbourne, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia,
30Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital, Boston,
Massachusetts, USA, 31Division of Human Genetics, Genome Institute of Singapore, Singapore, Singapore,
32Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands, 33Netherlands
Consortium for Healthy Ageing, Netherlands Genomics Initiative, the Hague, the Netherlands, 34Department
of Ophthalmology, Academic Medical Center, Amsterdam, the Netherlands, 35Department of Ophthalmology,
Leiden University Medical Center, Leiden, the Netherlands, 36The Netherlands Institute of Neuroscience
KNAW, Amsterdam, the Netherlands, 37Department of Medicine, National University of Singapore and
National University Health System, Singapore, Singapore, 38Saw Swee Hock School of Public Health, National
University of Singapore and National University Health System, Singapore, Singapore, 39Department of
Statistics and Applied Probability, National University of Singapore, Singapore, Singapore, 40Glaucoma Service,
The Rotterdam Eye Hospital, Rotterdam, the Netherlands, 41Department of Biochemistry, Yong Loo Lin School
of Medicine, National University of Singapore, 42Institute of Clinical Chemistry and Laboratory Medicine,
University Medical Center Mainz, Mainz, Germany, 43Department of Ophthalmology, University of Groningen,
University Medical Center Groningen, Groningen, the Netherlands, 44Department of Molecular Epidemiology,
Queensland Institute of Medical Research, Herston, Brisbane, Queensland, Australia, 45Preventive Cardiology
and Preventive Medicine/Center for Cardiology, University Medical Center Mainz, Mainz, Germany,
46Center for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany, 47German Center
2 | Human Molecular Genetics, 2017, Vol. 0, No. 0
for Cardiovascular Research (DZHK), partner site RhineMain, Mainz, Germany, 48Department of
Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison,
Wisconsin, USA, 49School of Medicine, Menzies Research Institute Tasmania, University of Tasmania, Hobart,
Australia, 50Department of Ophthalmology, Harvard Medical School and Massachusetts Eye and Ear Infirmary,
Boston, Massachusetts, USA and 51Department of Ophthalmology, Medical Faculty Mannheim of the Ruprecht-
Karls-University of Heidelberg, Heidelberg, Germany
* To whom correspondence should be addressed at: Stuart MacGregor, Statistical Genetics, QIMR Berghofer Medical Research Institute, Royal Brisbane
Hospital, Brisbane, Australia. Tel: þ 61 7 3845 3563, Email: Stuart.MacGregor@qimrberghofer.edu.au
Abstract
Primary open-angle glaucoma (POAG), the most common optic neuropathy, is a heritable disease. Siblings of POAG cases
have a ten-fold increased risk of developing the disease. Intraocular pressure (IOP) and optic nerve head characteristics are
used clinically to predict POAG risk. We conducted a genome-wide association meta-analysis of IOP and optic disc param-
eters and validated our findings in multiple sets of POAG cases and controls. Using imputation to the 1000 genomes (1000G)
reference set, we identified 9 new genomic regions associated with vertical cup-disc ratio (VCDR) and 1 new region associated
with IOP. Additionally, we found 5 novel loci for optic nerve cup area and 6 for disc area. Previously it was assumed that gen-
etic variation influenced POAG either through IOP or via changes to the optic nerve head; here we present evidence that some
genomic regions affect both IOP and the disc parameters. We characterized the effect of the novel loci through pathway ana-
lysis and found that pathways involved are not entirely distinct as assumed so far. Further, we identified a novel association
between CDKN1A and POAG. Using a zebrafish model we show that six6b (associated with POAG and optic nerve head vari-
ation) alters the expression of cdkn1a. In summary, we have identified several novel genes influencing the major clinical risk
predictors of POAG and showed that genetic variation in CDKN1A is important in POAG risk.
Introduction
In primary open-angle glaucoma (POAG), loss of retinal ganglion
cells and nerve fibres manifests itself clinically as optic nerve
damage, which leads to visual field loss and, eventually in 15%
of these to visual impairment and blindness (1–3). The optic
nerve damage is characterized by an increase in cup area, the
central portion of the optic nerve head (or optic disc), and/or a
decrease in the rim area (the area of the disc occupied by the
retinal nerve fibre axons). This damage can be quantified by the
vertical cup-disc ratio (VCDR), comparing the vertical diameter
of the cup with the vertical diameter of the total optic disc. The
VCDR ranges from 0 to 1. In the clinical setting, optic nerve
heads with a VCDR above 0.7 or an asymmetry between eyes
above 0.2 are considered to be suspect for glaucoma. The inter-
pretation of VCDR depends on the disc area, i.e. discs with larger
area have on average a higher VCDR and the cut-off point be-
tween a normal and abnormal VCDR might be higher (4).
Elevated intraocular pressure (IOP) is a well-recognized risk
factor for POAG and current therapies lower IOP by various mech-
anisms; eye pressure is considered to be normal between 8 and
21 mmHg, although many eyes with eye pressure in this range
can exhibit glaucomatous optic nerve features. Analyses of first-
degree relatives of POAG patients have shown that the sib relative
risk is 10.46 2.5 (5). Classic twin studies in POAG are lacking and
there is no consensus on heritability for POAG, but work by
Cuellar-Partida et al. estimated the heritability of POAG based on
genome-wide array data at 0.4260.09 (6). Several genome-wide
association studies (GWAS) have identified new POAG genes by
examining POAG directly or studying endophenotypes like VCDR
and IOP (7–16). Several genes associated with VCDR and IOP -
CDKN2B-AS1, SIX6 (VCDR); and CAV1/CAV2, TMCO1, ABCA1 and
ARHGEF12 (IOP) - are associated with POAG. Notably, no genes
have been genome-wide associated with both VCDR and IOP.
Charlesworth et al. previously found a genetic correlation between
VCDR and IOP (RhoG¼ 0.45, P¼ 0.0012), however, genes underlying
this relationship have not yet been identified (17).
The aims of this study were to (1) identify new genes associ-
ated with the POAG endophenotypes IOP, VCDR, cup area, and
disc area, and ultimately POAG, using the 1000 Genomes imput-
ations reference panel, and (2) investigate the genetic overlap
between the different endophenotypes. To accomplish these
aims we performed a meta-analysis of GWAS of these four traits
within the International Glaucoma Genetics Consortium (IGGC).
Results
Intraocular pressure
We first conducted a meta-analysis of GWAS in the European
cohorts. Top hit variants were replicated in the meta-analysis of
the Asian cohorts. Next, we performed a meta-analyses of the
European and Asians cohorts. After removal of single nucleotide
polymorphisms (SNPs) with minor allele frequency (MAF)< 0.01
and low imputation quality, approximately 8 million SNPs were
included. Whilst the meta-analysis of individuals of European des-
cent yielded no novel associations, combined meta-analysis of in-
dividuals of European and Asian descent (n¼ 37,930, k¼ 1.05;
Supplementary Materials, Figs S1A and B, S2B) yielded nine gen-
omic regions reaching genome-wide significance, of which eight
genomic regions were already known (Supplementary Materials,
Figs S1A and B, S2B, and Table S3) (9,11,13). The peak SNP in the
new genomic region was rs55796939 on chromosome 11q25 near
ADAMTS8 (Supplementary Materials, Figs S3 and S4).The esti-
mated heritability (h2) of IOP using the LD score regression method
(18) and the summary statistics of European-only meta-analysis
was 0.13.
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Vertical cup-disc ratio
In the meta-analysis of individuals of European descent
(n¼ 23,899, k¼ 1.08), 21 genomic regions were genome-wide sig-
nificant (Supplementary Materials, Figs S5A, S6A and Table S4).
Five genomic regions were novel (near to the genes RPE65 on
chr. 1p31, F5 on chr. 1q23, PDZD2 on chr. 5p13.3, RREB1 on chr.
6p25, and DGKB on chr. 7p21.2) (Supplementary Materials, Figs
S7 and S8); the other genomic regions have been previously
associated with VCDR or cup area, two highly correlated traits
(19–21). Of the five novel genomic regions, RREB1 (P-value¼ 4.13
 103) was nominally significant in the analysis of individuals
of Asian descent (n¼ 8,373, k¼ 1.01). In the combined analysis
(n¼ 32,272, k¼ 1.06), another four novel genomic regions, near
to the genes VCAN on chr. 5q14.3, PSCA on chr. 8q24.2, ENO4 on
chr. 10q25.3, and RBM23 on chr. 14q11.2 (Supplementary
Materials, Figs S5B and S6B), were genome-wide significant
leading to a total of nine (5þ 4) novel genomic regions associ-
ated with VCDR. Of these novel genomic regions, F5 has been
associated with the disc area previously (21). Disc area influ-
ences the VCDR (22), and therefore we corrected VCDR for disc
area in a secondary analysis. After correction for disc area, the b
(P-value) decreased from 0.007 (2.15  109) to 0.002 (5.60 
102) in the subset with disc area available, suggesting that F5
acts primarily on disc area and secondary to VCDR through its
relation to disc area. The calculated h2 of VCDR using the
European -only meta-analysis was 0.31.
Cup area
The meta-analysis of individuals of European descent
(n¼ 22,489, k¼ 1.06) yielded 17 genome-wide significant regions
of which 14 regions were already implicated for cup area or
VCDR (Supplementary Materials, Figs S9A, S10A and Table S5)
(20,21). There were three novel associations on chr. 1q42.11 near
CDC42BPA, chr. 8q21.11 near CRISPLD1, and on chr. 15q26.3 near
FAM169B (Supplementary Materials, Figs S11 and S12).
CDC42BPA has previously been associated with disc area and
the fact that the association with cup area adjusting for disc
area is genome-wide significant suggests an independent effect
on cup area. In the combined analysis of European and Asian in-
dividuals (n¼ 29,828, k¼ 1.06, Supplementary Materials, Figs S9B
and S10B) all loci except FAM169B and CRISPLD1 remained
genome-wide significant, and there was one additional
genome-wide significant SNPs at chr. 6p21.2 (CDKN1A) and one
highly suggestive significant SNP at chr. 9q34.2 (ABO; previously
associated with IOP). For cup area the estimated h2 was 0.27.
Disc area
The meta-analysis of individuals of European descent
(n¼ 22,504, k¼ 1.06) resulted in 13 genome-wide significant re-
gions, of which two were not previously associated with disc
area: UGT8 on chr. 4q26 and CTNNA3 on chr. 10q22.2
(Supplementary Materials, Figs S13A, S14A, S15, S16, and Table
S6). These SNPs were not significant in the meta-analysis of in-
dividuals of Asian descent (n¼ 7,307, k¼ 1.02). An additional
four SNPs reached genome-wide significance in the combined
meta-analysis (n¼ 29,811, k¼ 1.07): PRDM16 on chr. 1p36.23-p33,
GADD45A on chr. 1p31.2, VGLL4 on chr. 3p25.3, and ASB7 on chr.
15q26.3 (Supplementary Materials, Figs S13B and S14B). The
estimated h2 for disc area was 0.27.
Characterization of the lead association signals
In total, 82 SNPs were associated with one or more of the above
endophenotypes. Functional characterization of the 82 SNPs
was performed using a range of bioinformatics tools (see
Methods). In total, 650 variants in linkage disequilibrium (LD)
with the 82 lead SNPs (R2>0.8) were examined for functional an-
notation. Overall, 61% (50/82) of the associated loci are in LD
with variants located in regulatory regions according to the
ENCODE data (e.g. DNase I hypersensitive sites, transcription
factor binding sites and motifs; see Supplementary Material,
Table S7). We investigated the expression levels of the identified
candidate genes using the UniGene database (23). Of all re-
viewed genes, CDKN1A, PAX6 and DUSP1 showed the highest
number of transcripts per million in the eye (Supplementary
Material, Table S8). According to the Ocular Tissue database
(24), CDKN1A is highly expressed in the optic nerve head, as
well as DUSP1, which also shows high expression in the trabecu-
lar meshwork. Both genes were associated with optic nerve
head parameters. PAX6 is highly expressed in the ciliary body
and retina; in this study we found it associated with disc area.
Other highly expressed genes in the optic nerve include EFEMP1
and ABI3BP, which are associated with cup area and disc area,
respectively (Supplementary Material, Table S9). To evaluate
whether associated genes are highly expressed in a particular
tissue, we performed tissue enrichment analyses for each trait
using suggestive SNPs (P-value< 1.00  1005) in DEPICT (25). No
FDR significant tissue enrichment was found for IOP, VCDR or
disc area. However, for cup area we found an enrichment for
membranes, joints, stem cells and other related connective tis-
sues. Similar results were found when suggestive SNPs associ-
ated with VCDR, cup and disc area (the optic nerve parameters)
were analyzed together (Table S10).
Gene-based test
To identify new loci not found through per-SNP tests, we per-
formed gene-based testing using VEGAS2. Reflecting the smaller
number of tests, our gene-based significance threshold is Pgene-
based< 0.05/24,769¼ 2.02  106 (24,769 genes tested). Using the
gene-based test we found several novel loci (Supplementary
Material, Table S11). C9 was significantly associated with IOP
(P-value 1.61  106); RARB (P-value 1.86  106) and HORMAD2-
AS1 (P-value 1.04  106) were associated with VCDR. These
genes were previously associated with the disc area, so the
novel associations with VCDR could possibly be driven by the
influence of the disc area on VCDR (21). In the cup area analysis,
the genes LRP10 (P-value 1.20  106) and REM2 (P-value 1.55 
106), and THSD4 (P-value 5.44  10 8) were significantly associ-
ated. The first two genes are located near to RBM23, which was
significant in the per-SNP test. THSD4 is located near to KPNB1,
which was associated with VCDR in our previous meta-analysis
(20). In the disc area analysis, we found two genes that were sig-
nificantly associated with disc area: ANKRA2 (P-value 8.42 
107) and LOC149950 (P-value 3.87  107).
Characterizing the overlap in biological pathways
involved in glaucoma endophenotypes
In total, 86 SNPs were associated with one or more of the above
endophenotypes. The effect estimates and P-values of these SNPs
for all four endophenotypes are shown in Table 1–3. ADAMTS8 (IOP
and VCDR, Tables 1 and 2B) and ABO (IOP and cup area, Table 1)
were genome-wide significantly associated with two traits. Of note
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Table 1. Single nucleotide polymorphisms (SNPs) that are genome-wide significantly associated with IOP and show and association with verti-
cal cup-disc ratio.
IOP VCDR Cup area Disc area
SNP Nearest gene A1/A2 b SE P b SE P b SE P B SE P
rs10918274 TMCO1 t/c 0.26 0.04 5.64E-12 0.005 0.002 8.38E-03 0.010 0.003 2.47E-03 0.000 0.006 9.49E-01
rs7635832 FNDC3B g/t 0.22 0.03 6.61E-13 0.001 0.001 3.35E-01 0.004 0.003 1.27E-01 0.002 0.005 7.08E-01
rs10281637 CAV1/CAV2 c/t 0.20 0.03 3.96E-13 0.004 0.001 5.28E-03 0.006 0.003 1.23E-02 0.002 0.005 6.01E-01
8:78380944* PKIA i/r 1.00 0.17 7.54E-09 0.000 0.010 9.74E-01 0.018 0.017 3.00E-01 0.018 0.031 5.61E-01
rs7815043 PKIA c/t 0.10 0.03 4.41E-05 0.001 0.001 3.13E-01 0.001 0.002 8.32E-01 0.002 0.004 5.66E-01
rs7944735 Many genes c/g 0.19 0.03 6.00E-11 0.001 0.001 4.37E-01 0.006 0.003 3.33E-02 0.000 0.005 9.68E-01
11:120357425 ARHGEF12 d/r 0.18 0.03 2.02E-09 0.001 0.001 6.12E-01 0.001 0.003 6.45E-01 0.001 0.005 8.38E-01
rs12794618 ARHGEF12 c/t 0.17 0.03 7.86E-09 0.001 0.001 4.14E-01 0.002 0.003 4.84E-01 0.004 0.005 4.53E-01
rs55796939 ADAMTS8 t/c 0.36 0.06 2.31E-08 0.003 0.003 3.61E-01 0.006 0.006 3.19E-01 0.003 0.010 7.95E-01
rs2472496 ABCA1 g/a 0.17 0.02 1.93E-13 0.004 0.001 6.83E-05 0.010 0.002 9.63E-07 0.003 0.004 4.75E-01
rs8176741 ABO a/g 0.24 0.04 3.47E-10 0.007 0.002 4.51E-05 0.019 0.003 7.12E-08 0.004 0.006 5.42E-01
rs9913911 GAS7 g/a 0.17 0.02 7.01E-12 0.006 0.001 1.84E-07 0.008 0.002 2.48E-04 0.001 0.004 8.41E-01
For these SNPs, the associations with the other traits are also included. SNPs that are Bonferroni significantly associated with other traits are shown in bold (P-val-
ue<5.37  104; 0.05/93). In the first rows, the SNPs genome-wide significantly associated with intraocular pressure (IOP) are shown. Next, the SNPs associated with
IOP, vertical cup-disc ratio (VCDR), and cup area are shown. Nearest gene, reference NCBI build37; A1, reference allele; A2, other allele; b, effect size on the endopheno-
type (IOP, VCDR, cup area or disc area) based on allele A1; SE, standard error of the effect size; i, insertion; d, deletion; r, reference. *This locus was not considered as
new because the signal came from only one INDEL (8:78380944).
Table 2A. Single nucleotide polymorphisms (SNPs) that are genome-wide significantly associated with at least one of the optic disc
parameters.
IOP VCDR Cup area Disc area
SNP Nearest gene A1/A2 b SE P b SE P b SE P B SE P
rs6804624 COL8A1 c/t 0.01 0.03 6.54E-01 0.008 0.001 8.63E-12 0.013 0.002 1.99E-08 0.020 0.004 9.67E-07
rs7916697 ATOH7 a/g 0.01 0.03 7.43E-01 0.018 0.001 2.46E-45 0.017 0.002 1.32E-12 0.094 0.004 1.34E-102
10:96008348 PLCE1 d/r 0.01 0.03 5.73E-01 0.007 0.001 4.57E-08 0.013 0.002 1.72E-08 0.015 0.004 2.22E-04
rs324780 TMTC2 g/a 0.03 0.02 2.79E-01 0.011 0.001 7.16E-23 0.016 0.002 1.57E-13 0.029 0.004 8.58E-13
rs4299136 ASB7 c/g 0.03 0.03 4.22E-01 0.010 0.002 2.68E-12 0.018 0.003 4.09E-10 0.024 0.005 4.02E-06
16:51461915 SALL1 r/i 0.02 0.03 4.34E-01 0.010 0.001 2.62E-13 0.013 0.003 6.78E-07 0.032 0.005 2.38E-12
rs4784295 SALL1 c/g 0.02 0.03 5.63E-01 0.009 0.001 3.93E-13 0.013 0.003 1.63E-07 0.031 0.005 1.12E-11
rs5752773 CHEK2 g/c 0.01 0.03 6.91E-01 0.012 0.001 1.49E-20 0.024 0.003 4.12E-21 0.024 0.005 1.48E-07
rs2092172 CARD10 a/g 0.00 0.03 8.86E-01 0.009 0.001 3.08E-12 0.011 0.003 3.34E-05 0.032 0.005 1.44E-11
rs7717697 VCAN c/t 0.01 0.02 7.21E-01 0.007 0.001 6.66E-09 0.009 0.002 1.19E-05 0.018 0.004 4.84E-06
rs1681739 ENO4 t/c 0.03 0.02 2.23E-01 0.006 0.001 2.44E-08 0.011 0.002 3.70E-07 0.019 0.004 1.85E-06
rs60779155 ASB7 a/g 0.02 0.04 6.61E-01 0.010 0.002 3.76E-10 0.019 0.003 3.75E-09 0.030 0.006 8.26E-08
rs1830890 PLCE1 g/a 0.01 0.02 8.14E-01 0.006 0.001 3.02E-08 0.012 0.002 1.06E-07 0.013 0.004 5.51E-04
rs482507 TMTC2 c/t 0.02 0.02 3.48E-01 0.011 0.001 2.19E-19 0.017 0.002 2.56E-14 0.030 0.004 4.49E-13
rs4436712 SIX6 t/g 0.04 0.02 1.47E-01 0.009 0.001 5.48E-14 0.025 0.002 1.50E-29 0.018 0.004 6.59E-06
rs738722 CHEK2 t/c 0.02 0.03 3.57E-01 0.012 0.001 4.94E-20 0.024 0.003 7.81E-22 0.021 0.005 2.63E-06
rs2684249 HSF2 c/t 0.03 0.02 2.08E-01 0.006 0.001 1.64E-07 0.012 0.002 3.04E-08 0.015 0.004 1.49E-04
rs34222435 ASB7 t/c 0.03 0.03 3.86E-01 0.010 0.002 3.07E-12 0.019 0.003 1.07E-10 0.025 0.005 2.98E-06
rs7916410 ATOH7 t/c 0.00 0.03 9.76E-01 0.018 0.001 1.14E-45 0.017 0.002 6.11E-12 0.097 0.004 7.06E-109
rs442376 TMTC2 c/t 0.03 0.03 3.09E-01 0.011 0.001 1.50E-17 0.017 0.002 3.18E-12 0.032 0.004 4.92E-14
rs1345467 SALL1 g/a 0.01 0.03 6.53E-01 0.009 0.001 4.96E-12 0.012 0.003 1.07E-06 0.032 0.005 6.41E-13
rs5762752 CHEK2 c/g 0.01 0.03 6.61E-01 0.011 0.001 4.83E-18 0.021 0.002 6.72E-19 0.023 0.004 2.26E-08
rs11129176 RARB a/g 0.02 0.03 4.17E-01 0.005 0.001 3.17E-05 0.010 0.002 1.01E-05 0.023 0.004 3.40E-08
rs1997404 COL8A1 g/t 0.03 0.03 3.24E-01 0.008 0.001 2.39E-11 0.013 0.002 7.71E-08 0.024 0.004 1.90E-08
rs34935520 SIX6 g/a 0.04 0.02 1.13E-01 0.009 0.001 7.95E-14 0.025 0.002 6.96E-29 0.023 0.004 7.61E-08
For these SNPs, the associations with the other traits are also included. Here the SNPs genome-wide significantly associated with at least one of the optic disc param-
eters and that are Bonferroni significantly associated with the other disc parameters are shown in bold (P-value<5.37  104; 0.05/93).Nearest gene, reference NCBI
build37; A1, reference allele; A2, other allele; b, effect size on the effect size on the endophenotype (IOP, VCDR, cup area or disc area) based on allele A1; SE, standard
error of the effect size; i, insertion; d, deletion; r, reference.
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is that there were different variants involved in ADAMTS8:
rs55796939 for IOP and rs4936099 for VCDR (r2¼ 0.03 between these
SNPs in 1000G European samples). Figure 1 shows the overlap in
associations across endophenotypes — we depict annotated genes
for which at least one SNP was genome-wide significant in at least
one trait — Overlap is defined as nominal significance or stronger
for the second trait. The figure shows as expected a strong overlap
in variants associated with disc area, cup area and VCDR. Further,
overlap is noted in genes associated with IOP, cup area and VCDR.
We next explored the genetic overlap between optic disc param-
eters and IOP using our GWAS results from the European-only
meta-analyses, which comprised a larger sample size (n¼ 22,489–
29,578). As expected genetic correlation between optic disc param-
eters was high; VCDR and cup area showed the highest correlation
(RhoG¼ 0.83, P-value< 1.0  10308), followed by VCDR and disc
area (RhoG¼ 0.62, P-value¼ 7.36  1023). The genetic correlation
between cup and disc area was 0.31 (P-value¼ 1.00 1004). No sig-
nificant genetic correlation was found between IOP and optic disc
parameters; the highest correlation was between IOP and VCDR
(RhoG¼ 0.06, P-value 0.3) (Table S12).
To further characterize the overlap in biological functions,
gene set enrichment of loci associated with IOP and optic disc par-
ameters was performed using DEPICT (25). We first investigated
enriched pathways or gene sets using only genome-wide associ-
ated SNPs. No significant pathways were found after FDR correc-
tion. However, the pathways involved in metabolic processes such
as "increased circulating leptin level", "abnormal fat cell morph-
ology" and "increased insulin sensitivity" were suggestive when
we analyzed the list of SNPs associated with VCDR, cup area and
disc area (FDR< 0.2, see Supplementary Material, Table S13). We
next searched for enriched pathways using suggestive SNPs (P-
value<1.0  105). We further investigated the potential overlap
in pathways across the endophenotypes, and found 57 significant
pathways when using VCDR, cup area and IOP variants, and 100
pathways when analysing suggestive VCDR, cup area and disc
area variants. Note that in the first analysis we investigated path-
ways enriched when IOP genes are taken into account, while in
the second one we analysed genes influencing the optic nerve
head characteristics. Due to a high degree of redundancy between
pathways, we clustered the significant pathways into meta-
pathways, resulting in 11 meta-pathways for VCDR, cup area and
IOP (Fig. 2A, Supplementary Material, Table S14); and 17 for VCDR,
cup area, and disc area (Fig. 2B, Supplementary Material, Table
S15). Most of the gene sets found in both analyses highlighted
pathways involved in cell differentiation, notch signalling, regula-
tory DNA binding and embryonic development, which reflects the
pathways found when VCDR and CA variants are analyzed
(Supplementary Material, Fig. S17). Furthermore, we found "abnor-
mal fat cell morphology" and "abnormal liver morphology" signifi-
cantly enriched; a key gene in these pathways is ABCA1. When
IOP genes are included the elongation factor, RNA Polymerase II
(ELL2) protein complex" shows an enrichment. When disc area
genes are included, pathways such as "blood vessel development",
"protein import into nucleus", "Thrombospondin 1 (THBS1) and
SMAD3 protein complex", and "abnormal eye morphology" were
significant. Key genes in the latter include: CDKN2B, FAT4, LRIG3,
SIX6, COL8A1, SOX11, RND3, BOC, WNT2B and CYP26A1.
From endophenotypes to primary open-angle glaucoma
To evaluate the implications of our findings in the context of glau-
coma, we examined the association between the genome-wide
significant SNPs found in this study and 4 independent POAG
studies (n¼ 6,429 cases and 41,404 controls). In total, 75 independ-
ent (i.e. R2<0.8) SNPs associated with one or more of the endophe-
notypes were assessed in the case/control studies. Of these, 32
were nominal significantly associated with POAG (P-value<0.05;
the chance that 32 SNPs of 75 SNPs have a P-value<0.05 is< 2.2 
1016), and 11 independent SNPs were Bonferroni significantly
associated with POAG (P-value 0.05/75¼ 6.67  104) (Table 4). Two
out of the 11 Bonferroni significant SNPs, the rs2487048 in the
ABCA1 gene and the 11:120357425 in the ARHGEF12 showed high
heterogeneity (I2). To estimate the common effect size we per-
formed a random effect meta-analysis. The odds ratio (OR) re-
mained almost the same for both variants, although P-values
were not significant after adjusting for multiple testing, which is
in line with the heterogeneity observed. All other nine SNPs sur-
passed the Bonferroni threshold for significance in both fixed and
TMCO1,
CAV1/CAV2,
ARHGEF12,
FNDC3B,
PKIA,
Chr 11p11.2,
ADAMTS8
ABCA1,
GAS7
ABO
COL8A1, ATOH7,
PLCE1, TMTC2,
ASB7, SALL1,
CHEK2, CARD10,
VCAN, ENO4,
SIX6, HSF2,
RARB
CDKN2B-AS1, SIX6, BMP2, 
FLNB, RERE, CDKN1A
PE65, PDZD2, DUSP1, REB1, 
DGKB, PLCE1, SSSCA1, 
ADAMTS8, DCLK1, FAM101A, 
RBM23, DHRS3, TRIB2, DUSP1, 
CRISPLD1, DDHD1, FAM169B, 
SALL1, BCAS3, FEMP1/PNPT1, 
FLNB, TRIOBP
CDC7/TGFBR3,
F5,
PSCA,
ABI3BP,
DCAF4L2,
ELP4/PAX6,
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Figure 1. Overlap between the genes associated with one or more endophenotypes. Genes with a genome-wide significant association for at least one trait are shown.
These genes are counted as overlapping genes if they are Bonferroni significantly associated with the other trait(s). Chr 11p11.2 (see intraocular pressure circle) means
a region on chromosome 11p11.2 that is associated with IOP and has many genes in it; the likely causative gene in this region is not identified yet. Genes in bold are
genes associated with primary open-angle glaucoma (POAG) in our meta-analysis of four case-control studies.*Genes associated with familial forms of POAG (e.g.
MYOC and OPTN) or found in case-control association studies which did not show an association with the endophenotypes explored in this study.
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random-effect models. The association between CDKN1A and
POAG is novel (OR¼ 1.14, P-value¼ 7.4  107). In our previous
paper, the SNP rs6054374 near to BMP2 was already associated
with POAG (OR¼ 0.92, P-value 3.74  103), but the most signifi-
cantly associated SNP in the current meta-analysis rs6107845 near
to BMP2 shows a slightly larger effect on POAG (OR¼ 0.89, P-val-
ue¼ 8.52  106). CDKN1A, the novel associated POAG candidate
gene belongs to the cyclin dependent kinase inhibitor (CDKN)
gene family as well as CDKN2A, CDKN2B/CDKN2B-AS1, which all
lie in a well-known glaucoma associated locus on chr.9p21.
Expression of cdkn1a after knockdown of six6b
in zebrafish
Previous studies have shown that the transcription factor SIX6
alters the expression of CDKN2A and CDKN2B (26,27). All three
genes (SIX6, CDKN2A and CDKN2B) are in loci associated with
POAG, suggesting a possible functional link between these
POAG-loci. Given that CDKN1A is part of the same gene family
as CDKN2A and CDKN2B we tested whether SIX6 also regulates
CDKN1A. To assess the potential for functional regulation of
CDKN1A through SIX6, we first performed in silico analyses and
observed that SIX6 binds to CDKN1A (core score¼ 0.812). Then
we used a previously studied zebrafish model (27), in which we
tested whether knockdown of six6b alters the expression of
cdkn1a in vivo. Knockdown of six6b was achieved using morpho-
lino technology (27). 85% of the knockdown embryos showed a
small eye phenotype, reduced optic nerve thickness and an up-
regulation of the expression levels of cdkn2a/cdkn2b, as observed
in previous studies (n¼ 220) (27,28). In zebrafish, there is only
one gene which is analogous to the human CDKN2A and
CDKN2B and it is referred to in this paper as cdkn2a/cdkn2b. We
evaluated the expression levels of cdkn1a in eyes of six6b defi-
cient embryos by RT-qPCR. A 41-fold overexpression of cdkn1a
Table 2B. Single nucleotide polymorphisms (SNPs) that are genome-wide significantly associated with vertical cup-disc ratio or with cup area
IOP VCDR Cup area Disc area
SNP Nearest gene A1/A2 b SE P b SE P b SE P B SE P
rs1925953 RPE65* t/a 0.02 0.02 3.26E-01 0.006 0.001 1.55E-07 0.010 0.002 1.50E-05 0.006 0.004 1.08E-01
rs72759609 PDZD2 c/t 0.04 0.05 3.50E-01 0.012 0.002 7.10E-09 0.020 0.004 1.98E-06 0.021 0.008 5.62E-03
rs114503346 DUSP1 t/c 0.12 0.08 1.27E-01 0.021 0.004 1.31E-08 0.035 0.007 2.90E-07 0.035 0.013 5.83E-03
rs4960295 RREB1 a/g 0.02 0.02 4.75E-01 0.007 0.001 2.49E-10 0.009 0.002 3.73E-05 0.012 0.004 3.29E-03
rs10274998 DGKB t/c 0.02 0.03 4.38E-01 0.008 0.001 4.68E-08 0.012 0.003 8.08E-06 0.011 0.005 2.65E-02
rs2157719 CDKN2B-AS1 c/t 0.04 0.02 9.81E-02 0.013 0.001 3.75E-35 0.024 0.002 3.31E-28 0.008 0.004 3.03E-02
rs3891783 PLCE1 g/c 0.04 0.02 1.01E-01 0.007 0.001 1.06E-10 0.011 0.002 3.28E-07 0.012 0.004 1.52E-03
rs1346 SSSCA1 t/a 0.05 0.03 1.20E-01 0.013 0.002 7.51E-18 0.019 0.003 9.31E-11 0.016 0.005 2.10E-03
rs4936099 ADAMTS8 c/a 0.03 0.03 2.38E-01 0.007 0.001 6.70E-09 0.013 0.002 4.96E-08 0.006 0.004 1.72E-01
13:36629905 DCLK1 d/r 0.02 0.03 5.70E-01 0.007 0.001 2.98E-08 0.018 0.002 2.20E-14 0.005 0.004 2.36E-01
rs7323428 DCLK1 t/g 0.02 0.03 4.13E-01 0.007 0.001 1.86E-08 0.019 0.002 1.67E-15 0.005 0.004 2.23E-01
rs8015152 SIX6 t/c 0.06 0.02 2.27E-02 0.010 0.001 2.86E-18 0.024 0.002 8.15E-26 0.011 0.004 6.18E-03
rs6107845 BMP2 a/g 0.03 0.02 2.80E-01 0.009 0.001 3.44E-17 0.017 0.002 2.90E-15 0.004 0.004 3.27E-01
rs6764184 FLNB t/g 0.05 0.03 5.03E-02 0.007 0.001 1.89E-08 0.015 0.002 1.30E-10 0.010 0.004 1.92E-02
rs7311936 FAM101A c/g 0.03 0.02 1.69E-01 0.006 0.001 2.48E-09 0.013 0.002 4.52E-09 0.003 0.004 5.14E-01
14:23388793 RBM23 r/d 0.02 0.03 3.99E-01 0.007 0.001 2.56E-08 0.013 0.003 2.01E-07 0.009 0.005 4.29E-02
rs3794453 RBM23 a/t 0.01 0.02 7.22E-01 0.007 0.001 7.25E-08 0.011 0.002 2.88E-07 0.009 0.004 3.11E-02
rs2252865 RERE t/c 0.05 0.03 4.11E-02 0.005 0.001 2.66E-05 0.014 0.002 1.33E-09 0.003 0.004 5.08E-01
IOP VCDR Cup area Disc area
SNP Nearest gene A1/A2 b SE P b SE P b SE P B SE P
rs13016883 TRIB2 c/g 0.01 0.03 5.64E-01 0.006 0.001 3.44E-06 0.016 0.002 1.83E-11 0.001 0.004 8.30E-01
rs35084382 DUSP1 c/t 0.10 0.07 1.32E-01 0.018 0.003 2.05E-08 0.033 0.006 2.17E-08 0.031 0.011 5.51E-03
rs117598310 CRISPLD1* t/g 0.05 0.05 3.10E-01 0.009 0.002 1.07E-04 0.021 0.004 1.66E-06 0.022 0.008 5.47E-03
rs1360589 CDKN2B-AS1 c/t 0.04 0.02 8.42E-02 0.013 0.001 1.43E-34 0.024 0.002 2.90E-28 0.008 0.004 4.45E-02
rs11613189 FAM101A t/c 0.03 0.03 2.27E-01 0.005 0.001 6.04E-06 0.016 0.002 2.01E-12 0.002 0.004 6.42E-01
rs2251069 DDHD1 c/t 0.01 0.02 7.29E-01 0.006 0.001 7.41E-08 0.013 0.002 1.20E-09 0.001 0.004 7.11E-01
rs6598351 FAM169B* t/c 0.02 0.03 5.26E-01 0.006 0.001 2.80E-05 0.012 0.003 1.77E-05 0.004 0.005 3.90E-01
rs11646917 SALL1 t/g 0.01 0.03 6.65E-01 0.009 0.001 4.83E-10 0.015 0.003 4.76E-09 0.015 0.005 1.30E-03
rs11867840 BCAS3 g/a 0.04 0.03 1.04E-01 0.006 0.001 4.86E-06 0.018 0.002 2.35E-13 0.011 0.004 1.00E-02
rs6054375 BMP2 t/g 0.03 0.03 2.45E-01 0.010 0.001 6.92E-15 0.018 0.002 1.83E-15 0.003 0.004 4.74E-01
rs3791679 EFEMP1/PNPT1 g/a 0.04 0.03 1.72E-01 0.005 0.001 1.17E-04 0.013 0.002 4.92E-08 0.003 0.004 5.14E-01
rs12494328 FLNB a/g 0.04 0.03 1.52E-01 0.006 0.001 1.56E-06 0.016 0.002 6.03E-11 0.009 0.004 4.50E-02
6:36592986 CDKN1A d/r 0.02 0.03 5.32E-01 0.006 0.001 1.92E-05 0.015 0.003 1.12E-08 0.006 0.005 2.09E-01
rs72852338 CDKN1A c/a 0.02 0.03 5.46E-01 0.006 0.001 3.29E-05 0.014 0.003 3.17E-08 0.005 0.005 2.97E-01
rs1074407 TRIOBP t/a 0.11 0.02 4.00E-06 0.006 0.001 3.32E-07 0.012 0.002 1.90E-08 0.008 0.004 3.92E-02
For these SNPs, the associations with the other traits are also included. Here the SNPs genome-wide significantly associated with vertical cup-disc ratio or cup area and
that are Bonferroni significantly associated with VCDR or cup area are shown in bold (P-value<5.37  104; 0.05/93).Nearest gene, reference NCBI build37; A1, reference
allele; A2, other allele; b, effect size on effect size on the endophenotype (IOP, VCDR, cup area or disc area) based on allele A1; SE, standard error of the effect size; i, in-
sertion; d, deletion; r, reference.
*Genome-wide associated in the European-only meta-analysis.
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in the eye of six6b knockdown embryos was found (P-val-
ue¼ 0.001) (Fig. 3), showing that in vivo downregulation of six6b
affects the expression levels not only of cdkn2a/cdkn2b but also
of cdkn1a, likely by binding to their sequence, repressing their
expression.
Discussion
This meta-analysis within the IGGC identified a novel genomic
region associated with IOP, nine genomic regions associated
with VCDR, five with cup area, and six with disc area. Eleven
genomic regions were associated with POAG. Of these regions,
the association between CDKN1A and POAG is novel.
We identified some specific loci that underlie the genetic
correlation between IOP and VCDR described earlier (17).
ADAMTS8 and ABO were genome-wide significant for both IOP
and VCDR or cup area. Variants found close to ABO (rs8176672
for cup area and rs8176741 for IOP) are in LD (r2>0.85) with
rs12216891, which lies in an enhancer and promoter histone
mark, suggesting a potential regulatory mechanism in that re-
gion. Furthermore, TRIOBP is genome-wide significant for cup
area, and reached a P-value of 3.42  106 for IOP. Interestingly,
TRIOBP is approximately 180 kb away from CARD10 which is
associated with disc area. There is a large overlap between
VCDR/cup area and disc area. Since VCDR is related to disc area,
it might be that the effect found for VCDR is due to the effect of
disc area. Most of these overlapping genes are still Bonferroni
significant in the cup area analysis in which we corrected for
disc area. Only CDC7/TGFBR3 and F5 are genome-wide signifi-
cant for VCDR as well as for disc area, but the effect is negligible
after correction for disc area, suggesting that these two genes
play primarily a role in disc area.
When suggestive SNPs (P-value<1.0  105) for VCDR and
cup area were analyzed together using DEPICT, we found an en-
richment of pathways involved in cell differentiation, develop-
ment, regulatory DNA binding and Notch signalling. Including
disc area SNPs to the VCDR and cup area analysis reveals add-
itional joint pathways: 1) eye and blood vessel development, 2)
Table 2C. Single nucleotide polymorphisms (SNPs) that are genome-wide significantly associated with vertical cup-disc ratio or with disc area
IOP VCDR Cup area Disc area
SNP Nearest gene A1/A2 b SE P b SE P b SE P B SE P
rs1192414 CDC7/TGFBR3 a/g 0.06 0.03 5.66E-02 0.014 0.001 1.78E-23 0.007 0.003 1.12E-02 0.087 0.005 7.44E-71
rs10753787 F5 t/c 0.03 0.02 1.69E-01 0.007 0.001 2.48E-09 0.005 0.002 2.14E-02 0.019 0.004 1.60E-06
rs2920293 PSCA g/c 0.00 0.02 8.57E-01 0.006 0.001 5.04E-09 0.007 0.002 9.17E-04 0.015 0.004 9.94E-05
rs4658101 CDC7/TGFBR3 a/g 0.06 0.03 4.46E-02 0.013 0.001 5.19E-23 0.007 0.003 1.13E-02 0.089 0.005 8.01E-77
1:169530520 F5/SELP i/r 0.02 0.03 4.22E-01 0.007 0.001 7.20E-07 0.005 0.003 5.44E-02 0.033 0.005 1.49E-12
rs2239854 F5/SELP a/g 0.03 0.03 2.64E-01 0.006 0.001 8.37E-07 0.005 0.002 5.04E-02 0.030 0.004 7.60E-13
rs9843102 ABI3BP a/g 0.00 0.03 9.84E-01 0.006 0.002 2.18E-04 0.002 0.003 5.88E-01 0.036 0.005 1.35E-11
8:88744441 DCAF4L2 d/r 0.01 0.02 6.98E-01 0.006 0.001 6.66E-07 0.006 0.002 4.53E-03 0.026 0.004 2.04E-11
rs6468996 DCAF4L2 t/c 0.00 0.02 9.12E-01 0.005 0.001 2.52E-07 0.006 0.002 2.14E-03 0.025 0.004 5.16E-11
rs61101201 ELP4/PAX6 g/t 0.02 0.03 5.51E-01 0.006 0.001 2.27E-06 0.005 0.002 4.51E-02 0.028 0.004 1.53E-10
rs56385951 CARD10 a/g 0.06 0.04 9.08E-02 0.011 0.002 1.87E-11 0.008 0.003 8.83E-03 0.047 0.006 1.49E-16
1:3046430 PRDM16 i/r 0.04 0.04 4.14E-01 0.007 0.002 5.35E-04 0.002 0.004 7.15E-01 0.044 0.007 1.79E-09
rs12028027 PRDM16 c/t 0.03 0.04 4.97E-01 0.007 0.002 2.15E-04 0.001 0.004 8.58E-01 0.043 0.007 1.46E-09
For these SNPs, the associations with the other traits are also included. Here the SNPs genome-wide significantly associated with vertical cup-disc ratio or with disc
area that are Bonferroni significantly associated with the VCDR or disc area are shown in bold (P-value<5.37  104; 0.05/93).Nearest gene, reference NCBI build37; b,
effect size on effect size on the endophenotype (IOP, VCDR, cup area or disc area) based on allele A1; SE, standard error of the effect size; i, insertion; d, deletion; r,
reference.
Table 3. Single nucleotide polymorphisms (SNPs) that are genome-wide significantly associated with optic nerve head parameters (cup area
and disc area)
IOP VCDR Cup area Disc area
SNP Nearest gene A1/A2 b SE P b SE P b SE P B SE P
1:227562773 CDC42BPA d/r 0.10 0.05 3.01E-02 0.003 0.002 2.37E-01 0.024 0.004 8.05E-09 0.055 0.008 3.65E-13
rs73102394 CDC42BPA t/c 0.09 0.05 4.34E-02 0.003 0.002 1.62E-01 0.022 0.004 4.16E-08 0.053 0.007 5.01E-13
rs11811982 CDC42BPA a/c 0.12 0.05 1.35E-02 0.004 0.002 5.54E-02 0.027 0.004 2.31E-10 0.062 0.008 2.02E-15
rs10021731 UGT8 c/t 0.01 0.02 8.23E-01 0.002 0.001 5.56E-02 0.002 0.002 2.68E-01 0.020 0.004 7.48E-07
rs12220165 CTNNA3* g/c 0.02 0.03 5.88E-01 0.004 0.002 1.47E-02 0.004 0.003 1.92E-01 0.023 0.005 2.51E-05
rs787541 U6, GADD45A c/g 0.07 0.03 7.08E-03 0.002 0.001 7.47E-02 0.002 0.002 4.82E-01 0.023 0.004 6.66E-08
rs1367187 DIRC3 c/t 0.07 0.03 9.74E-03 0.002 0.001 2.46E-01 0.002 0.003 4.87E-01 0.026 0.005 1.03E-08
rs2443724 VGLL4 c/g 0.00 0.02 8.62E-01 0.003 0.001 1.53E-02 0.000 0.002 9.15E-01 0.022 0.004 4.72E-08
rs1013830 CTNNA3 t/c 0.00 0.05 9.49E-01 0.007 0.002 4.80E-03 0.004 0.005 4.10E-01 0.046 0.008 5.45E-08
For these SNPs, the associations with the other traits are also included. SNPs that are Bonferroni significantly associated with other traits are shown in bold (P-val-
ue<5.37  104; 0.05/93). In the first rows, the SNPs genome-wide significantly associated with cup area are shown. Next, SNPs associated with only disc area, are
shown. Nearest gene, reference NCBI build37; A1, reference allele; A2, other allele; b, effect size on the endophenotype (IOP, VCDR, cup area or disc area) based on allele
A1; SE, standard error of the effect size; i, insertion; d, deletion; r, reference.
*Genome-wide associated with the European-only meta-analysis.
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cancer, 3) protein import into nucleus, and 4) thrombospondin 1
and SMAD3 complexes, related to the extracellular matrix. The
extracellular matrix pathway has been previously implicated in
optic nerve degeneration (20). ADAMTS8, COL8A1 and the novel
identified gene VCAN (versican) are involved in the metabolism
and composition of the extracellular matrix. Interestingly, mu-
tations in VCAN have been implicated in several
ophthalmologic disorders (29). Of interest, known POAG genes
also fit in the pathways identified in this study, for example
GAS7 and SIX6 play a role during development (27,30), TGFBR3
has been implicated in extracellular matrix regulation (31) and
in cancer as well as GMDS (32).
Common variants in CDKN2B and its antisense CDKN2B-AS1
have been robustly found associated with POAG. The gene
Figure 2. Pathways significantly enriched for: (A) Loci associated with the vertical cup-disc ratio, cup area and intraocular pressure (P-value<7.0  10-6 in the GWAS).
In total 11 meta-pathways were identified after clustering the 57 pathways identified by DEPICT. B) Loci associated with vertical cup-disc ratio, cup area and disc area
(P-value<1.0  10-5). In total 17 meta-pathways were identified after clustering the 100 pathways identified by DEPICT. In both figures, meta-pathways are represented
by nodes coloured according to statistical significance, and edges are scaled according to the correlation between meta-pathways. *The pathway Abnormal eye morph-
ology clustered with the meta-pathway Chordate embryonic development. ELL2¼Elongation Factor, RNA Polymerase II, DVL3¼Dishevelled Segment Polarity Protein 3,
THBS1¼Thrombospondin 1, RFX2¼Regulatory Factor X, 2. MDFI¼MyoD Family Inhibitor.
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Table 4. Association with primary open-angle glaucoma in a meta-analysis of four independent glaucoma case-control studies (ANZRAG,
NEIGHBORHOOD, Singapore, and Southampton).
Nearest gene A1/A2 OR (95% CI) OR (R) P-value P-value (R) Direction I2 P-value of heterogeneity
IOP SNPs
rs10918274 TMCO1 t/c 1.39 (1.30-1.50) 1.39 2.75E-19 1.37E-09 þþþþ 38.4 1.82E-01
rs7635832 FNDC3B g/t 0.89 (0.83-0.95) 0.91 1.41E-03 3.65E-02 —? 33.9 2.20E-01
rs10281637 CAV1/CAV2 c/t 1.13 (1.07-1.20) 1.13 2.32E-05 2.32E-05 þþþþ 0 4.89E-01
rs2487048 ABCA1 a/g 1.26 (1.19-1.33) 1.26 2.65E-15 3.82E-03 þþþþ 82.9 5.53E-04
rs8176741 ABO a/g 1.07 (0.99-1.17) 1.04 7.36E-02 5.25E-01 þ-þ 58.5 6.51E-02
rs7944735 Many genes (NUP160, PTPRJ) c/g 1.06 (1.01-1.13) 1.07 2.99E-02 2.99E-02 þþþþ 0 8.99E-01
11:120357425 ARHGEF12 d/r 1.16 (1.09-1.23) 1.19 1.52E-06 3.02E-02 þþþþ 83.2 4.65E-04
rs55796939 ADAMTS8 t/c 1.07 (0.94-1.24) 1.17 2.72E-01 4.46E-01 þ?– 78.6 9.35E-03
rs9913911 GAS7 g/a 0.80 (0.76-0.84) 0.80 1.08E-17 1.08E-17 —- 0 7.50E-01
VCDR SNPs
rs1925953 RPE65 t/a 1.07 (1.02-1.13) 1.10 4.21E-03 2.01E-02 þþþþ 46.7 1.31E-01
rs1192414 CDC7/TGFBR3 a/g 1.08 (1.02-1.16) 1.08 9.26E-03 9.26E-03 þþþþ 0 7.27E-01
rs10753787 F5 t/c 0.97 (0.93-1.03) 0.97 3.67E-01 3.67E-01 —- 0 9.92E-01
rs6804624 COL8A1 c/t 0.99 (0.94-1.05) 0.99 8.14E-01 8.14E-01 —þ 0 8.42E-01
rs72759609 PDZD2 c/t 0.90 (0.83-0.99) 0.91 3.20E-02 3.20E-02 —- 0 9.53E-01
rs114503346 DUSP1 t/c 1.00 (0.80-1.25) 1.00 9.99E-01 8.80E-01 þ?-þ 42 1.78E-01
rs4960295 RREB1 a/g 0.99 (0.95-1.05) 1.00 9.50E-01 9.09E-01 þ-þ 4.6 3.70E-01
rs10274998 DGKB t/c 1.03 (0.98-1.10) 1.04 2.16E-01 2.16E-01 þþ-þ 0 5.38E-01
rs2157719 CDKN2B-AS1 c/t 0.69 (0.66-0.74) 0.69 1.29E-40 1.29E-40 —- 0 5.67E-01
rs1900005 ATOH7 a/c 1.01 (0.96-1.07) 1.01 6.98E-01 6.77E-01 þ-þþ 5.1 3.67E-01
10:96008348 PLCE1 d/r 1.02 (0.97-1.09) 1.04 3.38E-01 3.15E-01 þ-þ? 35.3 2.13E-01
rs1346 SSSCA1 t/a 0.90 (0.85-0.97) 0.91 2.41E-03 2.41E-03 —- 0 9.04E-01
rs4936099 ADAMTS8 c/a 0.94 (0.9-1.00) 0.94 5.75E-02 5.75E-02 —- 0 9.63E-01
rs324780 TMTC2 g/a 0.93 (0.89-0.99) 0.93 1.35E-02 1.35E-02 —- 0 7.69E-01
13:36629905 DCLK1 d/r 0.99 (0.94-1.05) 0.99 7.53E-01 8.00E-01 –þ- 6.2 3.62E-01
rs8015152 SIX6 t/c 1.21 (1.16-1.28) 1.19 3.90E-15 7.08E-05 þþþþ 62.4 4.62E-02
rs4299136 ASB7 c/g 1.03 (0.97-1.10) 1.03 3.55E-01 3.55E-01 þþ-þ 0 8.29E-01
16:51461915 SALL1 i/r 0.94 (0.89-1.00) 0.94 3.85E-02 3.85E-02 —- 0 7.82E-01
rs6107845 BMP2 a/g 0.89 (0.85-0.94) 0.91 1.02E-05 6.94E-03 —- 43.1 1.53E-01
rs5752773 CHEK2 g/c 0.92 (0.88-0.98) 0.92 4.63E-03 4.63E-03 —- 0 9.12E-01
rs2092172 CARD10 a/g 0.97 (0.92-1.04) 0.98 4.35E-01 4.35E-01 –þ- 0 7.76E-01
rs6764184 FLNB t/g 1.07 (1.02-1.13) 1.02 5.73E-03 7.66E-01 þþ-þ 86.1 8.14E-05
rs7717697 VCAN c/t 0.98 (0.93-1.04) 0.98 5.26E-01 5.26E-01 —? 0 7.30E-01
rs2920293 PSCA g/c 1.03 (0.98-1.09) 1.03 2.25E-01 2.25E-01 þþ-? 0 3.79E-01
rs1681739 ENO4 t/c 1.02 (0.97-1.08) 1.03 3.92E-01 3.99E-01 þ–þ 49.2 1.16E-01
rs7311936 FAM101A c/g 0.99 (0.95-1.04) 1.00 8.12E-01 8.59E-01 þ— 11 3.38E-01
14:23388793 RBM23 r/d 1.03 (0.98-1.10) 1.03 1.83E-01 1.83E-01 þþþ? 0 4.61E-01
Cup area SNPs
rs2252865 RERE t/c 1.11 (1.06-1.18) 1.11 5.76E-05 2.87E-02 þþ-þ 59.3 6.10E-02
rs4846112 DHRS3 a/g 0.95 (0.91-1.01) 0.96 1.18E-01 1.18E-01 —- 0 5.53E-01
1:227562773 CDC42BPA d/r 0.87 (0.79-0.97) 0.90 1.14E-02 2.11E-01 –þ? 48.6 1.43E-01
rs13016883 TRIB2 c/g 1.08 (1.03-1.14) 1.08 4.25E-03 4.25E-03 þþþ? 0 8.63E-01
rs35084382 DUSP1 c/t 1.04 (0.85-1.29) 1.05 6.72E-01 6.72E-01 þ?-þ 0 3.91E-01
rs117598310 CRISPLD1 t/g 1.08 (1.00-1.19) 1.09 5.39E-02 5.39E-02 þþþ 0 8.01E-01
rs1360589 CDKN2B-AS1 c/t 0.69 (0.66-0.73) 0.69 1.90E-42 1.90E-42 —- 0 6.47E-01
rs10998036 ATOH7 c/g 1.01 (0.96-1.08) 1.02 5.42E-01 5.72E-01 þ— 26 2.55E-01
10:96008348 PLCE1 d/r 1.02 (0.97-1.09) 1.04 3.38E-01 3.15E-01 þ-þ? 35.3 2.13E-01
rs1346 SSSCA1 t/a 0.90 (0.85-0.97) 0.91 2.41E-03 2.41E-03 —- 0 9.04E-01
rs482507 TMTC2 c/t 0.94 (0.89-0.99) 0.94 2.03E-02 2.03E-02 —- 0 7.46E-01
rs11613189 FAM101A t/c 0.99 (0.95-1.05) 0.99 8.25E-01 7.77E-01 þþ– 18.5 2.98E-01
rs7323428 DCLK1 t/g 0.99 (0.94-1.05) 1.00 7.83E-01 8.87E-01 þ-þ- 13.6 3.25E-01
rs2251069 DDHD1 c/t 0.95 (0.91-1.00) 0.96 7.62E-02 7.62E-02 –þ- 0 4.08E-01
rs4436712 SIX6 t/g 1.24 (1.19-1.31) 1.23 5.77E-18 1.52E-07 þþþþ 48.8 1.19E-01
rs6598351 FAM169B t/c 0.99 (0.93-1.06) 0.99 8.06E-01 8.06E-01 þ– 0 7.11E-01
rs11646917 SALL1 t/3g 0.98 (0.93-1.04) 0.98 5.49E-01 5.49E-01 –þþ 0 5.97E-01
rs11867840 BCAS3 g/a 1.06 (1.01-1.13) 1.06 1.83E-02 2.12E-02 þþþþ 8.3 3.51E-01
rs6054375 BMP2 t/g 0.89 (0.85-0.94) 0.91 8.52E-06 9.93E-03 —- 47.1 1.29E-01
rs738722 CHEK2 t/c 0.93 (0.89-0.99) 0.93 1.26E-02 1.26E-02 —- 0 9.05E-01
rs3791679 EFEMP1/PNPT1 a/g 0.96 (0.92-1.02) 0.96 2.23E-01 2.23E-01 —- 0 5.51E-01
(continued)
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CDKN1A, also known as p21, CIP-1 or WAF-1, belongs to the
same family as CDKN2B and also encodes a cyclin-dependent
kinase inhibitor. Upregulation of CDKN1A causes G1 arrest and
inhibits proliferation of the cell. Herein, for the first time, we
provide genome-wide significant evidence for association of
CDKN1A variants with cup area. Two prior small cohort studies
suggested a possible role of CDKN1A in POAG. Tsai et al. (33)
found an association between a codon 31 polymorphism in
CDKN1A and POAG in 58 patients and 59 controls from China
(OR¼ 2.39 [1.14–5.01]). Saglar et al. found no statistically signifi-
cant association between the codon 31 polymorphism and
POAG in 75 patients and 119 controls from Turkey (OR¼ 1.70, P-
value¼ 0.25) (34). Our study provides strong evidence for the
role of CDKN1A in POAG risk in a large sample consisting of
6,429 cases and 41,404 controls and shows the first convincing
evidence for an association of CDKN1A and POAG in individuals
of European descent. A potential functional interaction between
POAG-loci (i.e. SIX6 and CDKN genes) has been shown previ-
ously (26,27). We performed in vivo studies in embryonic zebra-
fish eye and found that knockdown of six6b upregulates both
cdkn2a/cdkn2b and cdkn1a. The mechanism behind the genetic
variation in SIX6, and the CDKN genes remains obscure.
However, in a recent study, Skowronska-Krawczyk et al. showed
that SIX6 regulates the expression of CDKN2A in the context of
IOP elevation (26). More comprehensive studies at the individual
tissue level e.g. retinal ganglion cell layer or optic nerve should
be performed to evaluate the consequences of the genetic vari-
ation associated with POAG; for example, if associated variants
in SIX6 lead to up-regulation of CDKN genes.
Table . (Continued)
Nearest gene A1/A2 OR (95% CI) OR (R) P-value P-value (R) Direction I2 P-value of heterogeneity
rs12494328 FLNB a/g 1.13 (1.07-1.20) 1.13 1.28E-05 5.89E-04 þþ-þ 26.9 2.50E-01
rs6804624 COL8A1 c/t 0.99 (0.94-1.05) 0.99 8.14E-01 8.14E-01 —þ 0 8.42E-01
6:36592986 CDKN1A d/r 1.14 (1.09-1.21) 1.15 7.74E-07 1.04E-04 þþþþ 36.6 1.93E-01
rs2684249 HSF2 c/t 0.92 (0.88-0.97) 0.94 1.08E-03 1.66E-01 —þ 63.3 4.25E-02
rs8176672 ABO t/c 1.00 (0.91-1.11) 1.00 9.49E-01 9.49E-01 þ-? 0 3.69E-01
rs4936099 ADAMTS8 c/a 0.94 (0.90-1.00) 0.94 5.75E-02 5.75E-02 —- 0 9.63E-01
rs34222435 ASB7 t/c 1.03 (0.97-1.10) 1.03 3.66E-01 3.66E-01 þþ-þ 0 8.74E-01
rs1074407 TRIOBP t/a 1.04 (1.00-1.10) 1.04 4.92E-02 8.66E-02 þþþþ 32.9 2.15E-01
Disc area SNPs
rs4658101 CDC7/TGFBR3 a/g 1.08 (1.02-1.16) 1.08 7.81E-03 7.81E-03 þþþþ 0 7.22E-01
1:169530520 F5/SELP i/r 1.01 (0.96-1.08) 1.02 5.40E-01 5.40E-01 þþ-? 0 7.14E-01
rs11811982 CDC42BPA a/c 0.87 (0.80-0.97) 0.90 1.19E-02 8.28E-02 –þþ 20.5 2.87E-01
rs9843102 ABI3BP a/g 0.92 (0.86-0.98) 0.92 1.37E-02 1.37E-02 —- 0 6.24E-01
rs10021731 UGT8 c/t 1.01 (0.96-1.06) 1.01 6.82E-01 6.82E-01 –þþ 0 6.50E-01
8:88744441 DCAF4L2 d/r 1.03 (0.99-1.09) 1.04 0.1225 1.39E-01 þþ-þ 4.9 3.68E-01
rs12220165 CTNNA3 g/c 1.08 (1.01-1.16) 1.09 1.14E-02 1.14E-02 þþþþ 0 9.04E-01
rs7916410 ATOH7 t/c 1.00 (0.96-1.06) 1.00 7.63E-01 7.45E-01 þ-þþ 3.9 3.73E-01
rs61101201 ELP4/PAX6 g/t 1.00 (0.94-1.06) 1.00 9.77E-01 9.77E-01 þ-? 0 9.63E-01
rs442376 TMTC2 c/t 1.04 (0.99-1.10) 1.05 7.94E-02 7.94E-02 þþþ 0 6.82E-01
rs1345467 SALL1 g/a 1.07 (1.01-1.14) 1.07 1.86E-02 1.86E-02 þþþþ 0 8.73E-01
rs5762752 CHEK2 c/g 0.92 (0.88-0.98) 0.92 4.90E-03 4.90E-03 —- 0 8.29E-01
rs56385951 CARD10 a/g 0.99 (0.92-1.07) 1.00 9.15E-01 9.15E-01 þ-þ- 0 9.88E-01
1:3046430 PRDM16 i/r 0.97 (0.87-1.10) 0.98 7.13E-01 8.72E-01 þ–? 63.9 6.28E-02
rs787541 U6, GADD45A c/g 0.98 (0.94-1.04) 0.98 6.10E-01 9.06E-01 –þþ 50.7 1.08E-01
rs1367187 DIRC3 c/t 0.95 (0.90-1.01) 0.96 1.11E-01 4.12E-01 þ-þ- 46.1 1.35E-01
rs2443724 VGLL4 c/g 0.91 (0.87-0.97) 0.91 1.04E-03 2.61E-02 –þ- 38 1.84E-01
rs11129176 RARB a/g 0.99 (0.94-1.05) 1.00 8.85E-01 9.93E-01 þ— 40.4 1.69E-01
rs1997404 COL8A1 g/t 1.00 (0.95-1.06) 1.00 9.60E-01 9.60E-01 þþþ 0 6.18E-01
rs34935520 SIX6 g/a 1.26 (1.20-1.33) 1.26 2.82E-20 6.73E-14 þþþþ 21.5 2.81E-01
rs60779155 ASB7 a/g 1.02 (0.96-1.10) 1.03 4.52E-01 4.52E-01 þ–þ 0 5.02E-01
Results are shown for the most significantly associated single nucleotide polymorphisms from the endophenotype analyses. Nearest gene, reference NCBI build37; A1,
reference allele; A2, other allele; OR, estimated odds ratio for allele A1; 95% CI, confidence interval; OR (R), estimated odds ratio for allele A1 in random effect meta-ana-
lysis; P-value (R), P-value in random effect meta-analysis; I2 statistic measuring heterogeneity on a scale of 0–100%; i, insertion; d, deletion; r, reference.
Figure 3. cdkn1amRNA expression change Overexpression of cdkn1a and cdkn2a/
cdkn2b in response to six6b depletion is shown. All samples expression were
normalized to the control gene sdha. Relative expression was calculated by set-
ting the wild-type expression level at 1. Values represent mean6 standard error
of the mean. *P< 0.05; **P< 0.005.
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Genetic variation in CDK inhibitor genes has been found
associated with various diseases and traits. SNPs close to
CDKN1A, for example, have been associated with electrocardio-
graphic measures (35) and colorectal cancer (36). While the
CDKN2A/CDKN2B and CDKN2B-AS1 locus has been found in
GWAS of Type 2 Diabetes (37), fasting glucose (38), intracranial
aneurysm (39), myocardial infraction (40), coronary heart dis-
ease (41) and various cancers, including basal cell carcinoma
(42), breast (43) and prostate (44) cancer, and glioma (45).
Interestingly, the same allele in CDKN2B that decrease risk of
POAG, was found associated with increased risk of glioma. The
functional significance of the genetic variation in the CDK genes
remains to be determined, possible mechanism in POAG might
be related with the disruption of a delicate balance between
proliferation and apoptosis.
It has been suggested that p53 plays a role in POAG, espe-
cially in POAG with paracentral visual field loss (46).
Intriguingly, p53 has been also related to the CDK-inhibitors
and to four of the new genes pointed out by this study
(GADD45A, PDZD2, RREB1 and PSCA). GADD45A is involved in
growth arrest through p53-dependent and independent mech-
anisms (47,48) and can interact via CDKN1A (49). PDZD2 is a
tumour suppressor gene, reported to activate p53 by transcrip-
tional regulation (50). RREB1 has an effect on p53 by binding to
its promotor and transactivates its expression (51). While PSCA
expression correlates with the expression of p53 in choriocar-
cinoma, suggesting a role of PSCA in cell growth through p53-
related pathways (52). Other genes play a role in apoptosis or
cell growth via other mechanisms than p53: VGLL4 inhibits Bax-
and TNFa-induced apoptosis (53) and DGKB is a regulator of
diacylglycerol, which is important for cell growth and differenti-
ation. UGT8 plays a role in the biosynthesis of the sphingolipids
of myelin membranes of the central and peripheral nervous
system; sphingolipids are also implicated in apoptosis (54).
Another interesting novel gene is RPE65 (retinal pigment epi-
thelium -specific protein 65kDa). This gene has been associated
with retinitis pigmentosa (RP) (55,56) and Leber congenital am-
aurosis type 2 (LCA2) (57). As the name implies, the encoded
protein is located in the retinal pigment epithelium (58). Both
diseases (RP and LCA2) are not characterized by an excavation
of the optic nerve head. However, we have checked several on-
line databases for expression in different tissues. In the eye, it is
also highly expressed in the optic nerve head (Tables S8 and S9)
suggesting that this gene could be involved in other ocular proc-
esses. Little expression is found in the brain, with no expression
in other tissues or organs in the body. Future studies are neces-
sary to confirm our finding.
Of the genes identified by gene-based testing, C9 (comple-
ment component 9) is especially interesting. Its protein is part
of the membrane attack complex (MAC), together with the pro-
teins C5b, C6, C7, and C8. This complex activates several steps
that lead to cell death, and cells protect themselves by removing
the complex through endocytosis. Caveolin is one of the pro-
teins involved in endocytosis and the CAV1/CAV2 genes are
associated with IOP and POAG. It has been shown that inhib-
ition of caveolin-1 inhibits the endocytosis of MAC (59).
To our best knowledge, this meta-analysis is the largest
study of IOP and optic nerve head parameters to date, using
well-characterized datasets from populations world-wide.
A limitation of our study is the lack of an available dataset for
replication of the novel associations detected by combined
European and Asian ancestry samples. However, the heterogen-
eity of these novel genomic regions is generally low in the
meta-analysis. For VCDR, cup area, and disc area we have
identified novel SNPs in the analysis of individuals with
European ancestry. Of the nine novel associations found in
these populations (RPE65, PDZD2, RREB1, DGKB for VCDR;
CDC42BPA, CRISPLD1 and FAM169B for cup area; and CTNNA3
and UGT8 for disc area), only RREB1 was nominally significant in
the individuals with Asian ancestry. Five of the seven non-
significant SNPs in the individuals with Asian ancestry had an
effect estimate in the same direction. As the analysis in individ-
uals with Asian ancestry contains a smaller number of individ-
uals, this could be due to lack of power.
We have identified 21 genetic variants associated with POAG
endophenotypes: IOP, VCDR, cup area, and disc area. The effect
estimates of single SNP associations are small. We expected
small effects of many SNPs, since glaucoma endophenotypes
are highly polygenic traits (60). Although individual SNP effects
are small, the joint effect of the various genetic variants could
yield a clinical relevant parameter. These association results do
not imply that the variants described here have a causal effect.
Fine-mapping and functional studies are required to identify
the causal variants tagged by our findings and the exact mo-
lecular mechanisms involved in POAG. Although the overlap be-
tween IOP-loci and the optic disc parameters-loci is not large,
this is the first study showing a genome-wide significant evi-
dence of the genetic correlation between IOP and VCDR; we ex-
pect that larger sample sizes and improved imputation
accuracy may help to find more of the loci underlying the gen-
etic correlation between these two endophenotypes. Of the
novel associations, CDKN1A is strongly associated with POAG,
This finding is in line with other studies (26), pointing to the
CDK-inhibitor genes as key players in the development of
POAG. The p53 pathway has been implicated in POAG and inter-
act in different cellular contexts with four of the new genes
pointed out by this study (GADD45A, PDZD2, RREB1 and PSCA).
Functional studies need to be performed to assess the role of
p53 and CDK-inhibitors in the pathophysiology of POAG. A more
comprehensive study of these mechanisms may inform the de-
velopment of new therapies for POAG.
Materials and Methods
Study design
We performed a meta-analysis on directly genotyped and
imputed SNPs to the 1000 Genomes reference panel. We ana-
lyzed four outcomes: IOP, VCDR, cup area, and disc area; the
same approach was used for all four outcomes. In the first stage,
we conducted a meta-analysis of GWAS including 22,489–29,578
individuals of European ancestry. Subsequently, we evaluated
the genome-wide significant SNPs from the first stage in a
meta-analysis of GWAS including 7,307–8,373 individuals of
Asian ancestry. Finally, we performed a mega/meta-analysis of
GWAS from all individual studies including individuals of
European and Asian ancestry. We subsequently tested the effect
of all genome-wide significant SNPs on POAG in four independ-
ent case-control studies (n¼ 6,429/41,404). These cases are not
part of our primary meta-analyses which focused on quantita-
tive traits in the general population (IOP, VCDR, cup area and
disc area). Three of the case-control studies were of European
ancestry (7,61,62) and one of Asian ancestry (63).
Subjects, phenotyping and genotyping
All 19 studies included in this meta-analysis are part of the
IGGC (Table S1A). Details for each individual study can be found
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in Supplementary Material and Tables S1B and C and S2. The
ophthalmological examinations included measurements of IOP
and optic nerve head assessment. All 19 studies contributed to
the IOP mega/meta-analysis, 18 to the VCDR and 16 to the cup
area and disc area mega/meta-analysis. Validation of mega/
meta-analysis results was performed in four independent POAG
case-control studies. Studies performed genomic imputation
using 1000 Genomes phase 1 reference samples. Study-specific
quality control can be found in the Supplementary Material. All
studies were performed with the approval of their local medical
ethics committee, and written informed consent was obtained
from all participants in accordance with the Declaration of
Helsinki.
Statistical analysis
In the IOP analysis, individuals who underwent IOP-lowering
laser or surgery were removed from the analysis; in individuals
receiving IOP-lowering medication, the IOP value was multi-
plied by 1.3 to estimate a pre-medication IOP value (64). The
mean IOP, VCDR, cup area, and disc area of both eyes was used
for the analyses. SNPs with MAF< 0.01 and imputation quality
scores<0.3 (proper-info of IMPUTE) or R2< 0.3 (MACH) were
removed from the analyses. Each individual study performed a
linear regression between each endophenotype (IOP, VCDR, cup
area, and disc area) and the SNPs, under the assumption of an
additive model for the effect of the risk allele. Analyses were ad-
justed for age, sex and the first five principal components (for
population-based studies) or family structure (for family-based
studies).
We performed an inverse variance weighted fixed-effect
meta-analysis with METAL software (65). P values for hetero-
geneity were calculated by using the Cochran’s Q-test for het-
erogeneity. SNPs with a P-value for heterogeneity<0.001 were
removed from the results, as well as SNPs only present in three
studies. We used the ‘genomic control’ option in METAL to cor-
rect the standard error of each individual study for estimated
genomic inflation. To evaluate if our results exhibit signs of
population stratification we estimated the intercept using the
LD score regression method (18) in the European-only meta-
analyses. The intercept, which estimates inflation after remov-
ing polygenic signals, was: 1.0142 for IOP, 1.0199 for VCDR,
1.0074 for cup area and 1.0167 for the disc area (Table S16).
In the meta-analyses of individuals with European ancestry,
a P-value<5.0  108 (the genome-wide threshold of associ-
ation) was considered significant. In the second stage, these
genome-wide significant SNPs were validated in individuals
with Asian ancestry, and in this look-up a p value<0.05 was
considered significant. Finally, in the mega/meta-analysis of in-
dividuals with European and Asian ancestry a P-value of<5.0 
108 was considered significant. In total, we identified 75 inde-
pendent SNPs across different genomic regions for all the traits
together. Therefore, the significance level after Bonferroni cor-
rection in the meta-analysis of POAG cohorts was¼ 6.67  104
(0.05/75 independent SNPs). To estimate the common effect size
of the top SNPs associated with IOP, optic disc parameters
and their effect in the look-up in the POAG cohorts a
random-effect meta-analysis was performed using plink (66)
http://pngu.mgh.harvard.edu/purcell/plink/ parameter –meta-
analysis. Manhattan, regional and forest plots were made using
R (67) and LocusZoom (68).
The genetic correlation between optic disc parameters
(VCDR, cup and disc area) and IOP was estimated using the LD
score regression method (18,69). GWAS summary statistics from
the Europeans-only meta-analyses were used to calculate the
genetic overlap. To restrict the analyses to well imputed SNPs,
we included only SNPs with MAF> 0.01 that were present in
HapMap3. GWAS data were harmonized using the munge_sum-
stats.py function. For analyses, we used the pre-computed LD
scores for Europeans eur_w_ld_ch available at https://github.
com/bulik/ldsc/wiki. The ldsc.py function (with all default set-
tings) was used to calculate the genetic correlation between
traits. In addition, we calculated the heritability (h2) estimates
from the GWAS meta-analysis using the same function.
Gene-based test using VEGAS
A gene-based test was performed using the VEGAS2 software
(70), with a 50kb gene boundary. We used the parameter ‘-top
100’ (default) to perform gene-based tests. This parameter con-
siders association test statistics of all variants mapped to a gene
to compute gene-based test statistics. The 1000 Genomes
European and Asian populations were used as a reference to
calculate LD for European and Asian ancestry data respectively.
After calculation of gene-based test statistics for Asian and
European ancestry populations separately, meta-analyses were
conducted using Fisher’s method for combining P-values.
Functional characterization, expression data, zebrafish
and gene-set enrichment
We investigated for evidence of regulatory functions of associ-
ated loci HaploReg version 2 (71) and Regulomedb version 1.1
(72). We investigated the expression of the associated genes
using NCBI’s UniGene (23) and The Ocular Tissue Database (24).
We also investigated the expression of cdkn1a in a six6b knock-
down zebrafish and used DEPICT to investigate gene-set enrich-
ment. More information about these analyses can be found in
the Supplementary Material.
Data access
Access to the summary association statistics for IOP
and optic disc parameters is available at https://www.dropbox.
com/sh/3j2h9qdbzjwvaj1/AABFD1eyNetiF63I5bQooYura?dl¼0.
Supplementary Material
Supplementary Material is available at HMG online.
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